Nanobiotix S.A. (0QAV)
LSE
Closed
Aug 24, 2026
Day's Range
33.8052 wk Range
7.00Overview - 0QAV - Nanobiotix S.A.
Key Statistics
Valuation
Enterprise Value
1.84B
EV / EBITDA
‪-176.20‬
Profitability
Profit Margin
‪-73.51%‬
Operating Margin
‪-196.42%‬
Return on Assets
‪-10.06%‬
Ownership
Shares Outstanding
19.61M
Float
31.94M
Held by Insiders
‪15.54%‬
Held by Institutions
‪36.12%‬
Price stats
Beta
‪0.56‬
50-Day Avg
‪6.68‬
200-Day Avg
‪6.55‬
Market Cap - 0QAV - Nanobiotix S.A.
Peers - 0QAV - Nanobiotix S.A.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0QAVLSENanobiotix S.A.731.90MMarket Cap+78.64%52-week change—P/E (Trailing)‪-73.51%‬Profit Margin
- 0MGBLSEGenmab A/S173.69BMarket Cap+27.59%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.34BMarket Cap+29.12%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+31.55%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.72.10BMarket Cap+82.56%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE52.61BMarket Cap+34.75%52-week change42.42P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.47%52-week change128.71P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0QAV - Nanobiotix S.A.
About
Nanobiotix S.A. is a late-stage clinical biotechnology company specializing in physics-based nanomedicines to revolutionize cancer treatment. Headquartered in Paris, France, with offices in the United States, it pioneers nanotechnology that enhances radiotherapy's efficacy. The company's lead candidate, NBTXR3…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
